# The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

> **NCT05062330** · PHASE3 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 361 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** Reproxalap Ophthalmic Solution (0.25%)
- **DRUG:** Vehicle Ophthalmic Solution

## Key facts

- **NCT ID:** NCT05062330
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-28
- **Primary completion:** 2022-03-04
- **Final completion:** 2022-03-04
- **Target enrollment:** 361 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062330, "The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05062330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*